



## **Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020**

April 27, 2020

SEATTLE, April 27, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2020 after market close on Tuesday, May 12, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the "Investors" section of the company website at: [www.adaptivebiotech.com](http://www.adaptivebiotech.com). The webcast will be archived and available for replay within 24 hours after the event.

### **About Adaptive Biotechnologies**

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit [adaptivebiotech.com](http://adaptivebiotech.com) and follow us on [www.twitter.com/adaptivebiotech](https://www.twitter.com/adaptivebiotech).

### **Investor Contact:**

Carrie Mendivil  
[investors@adaptivebiotech.com](mailto:investors@adaptivebiotech.com)

### **Media Contact:**

Beth Keshishian  
[media@adaptivebiotech.com](mailto:media@adaptivebiotech.com)



Source: Adaptive Biotechnologies